⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Translational and Clinical PharmacologyOpen Access

Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025

Seoyoung Koo Chae Yeon Kim Jeong Hyeon Lim Eunyoung Lee In Young Kim Young G. Shin Hanlim Moon

View Full Paper

Ask AI

Bookmark

Share

Key Points

To correct inaccuracies in the assessment of exposure-safety relationships for antibody-drug conjugates (ADCs) approved by the FDA.
Review of antibody-drug conjugates approved from 2000 to 2025.
Identification and correction of errors in safety data presented in previously published tables.
An error was identified in the classification of interstitial lung disease for datopotamab deruxtecan.
Corrected safety data is now accurately reflected in the updated summary of E-R relationships.

Implication

This review corrects an error in safety assessments of antibody-drug conjugates, highlighting accurate FDA evaluations.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koo et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc4fa79560c99a0a1e89 https://doi.org/10.12793/tcp.2026.34.e3

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Learnings from Approved Antibody‐Drug Conjugates: Clinical Pharmacology PerspectivesHuman Clinical Trial · 2026 · 2 citations
2Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumorsRetrospective Study · 2026
3Antibody–drug conjugates: a practical review on clinical management of toxicitiesSystematic Review · 2026
4Postmarketing Safety Signals of Antibody–Drug Conjugates Compared to Traditional Therapies in Breast Cancer: A FAERS-Based Study2025
5Toxicity and efficacy of antibody–drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials2025 · 10 citations

More related papers

A real-world study of adverse event profiles associated with the four key components of antibody–drug conjugates based on the FAERS database2026
Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies: A FAERS analysis (2020–2025).2026
Antibody drug conjugates: Design implications for clinicians2024

More from Translational and Clinical Pharmacology

Incidence and sex-related risk factors of linezolid-associated adverse drug reactions identified through electronic health recordsThu,
Pioneering pharmacometrics practice in Korea: an eight-year retrospective analysis of 192 projects from the first dedicated service organization (2016–2024)Thu,